Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | TSHR | P16473 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7021479 | 0.86 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNATSHRMEN1KMT2A | |
| SCHEMBL1421294 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNATSHRMEN1KMT2A | |
| SCHEMBL28091841 | 0.85 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNATSHRMEN1KMT2A | |
| SCHEMBL19049437 | 0.84 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNATSHRMEN1KMT2A | |
| SCHEMBL5035255 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNATSHRMEN1KMT2A | |
| SCHEMBL2848307 | 0.82 | MEN1 (0.63) | SMN1; SMN2LMNATSHRMEN1KMT2A | |
| SCHEMBL10119378 | 0.82 | TSHR (0.64) | SMN1; SMN2LMNATSHRMEN1KMT2A | |
| SCHEMBL18997861 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNATSHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8813515 | 0.81 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNATSHRMEN1KMT2A | |
| SCHEMBL11196949 | 0.80 | GAA (0.53) | LMNATSHRALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | SMN1; SMN2 599/4885LMNA 3896/4885TSHR 3666/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | SMN1; SMN2 599/4885LMNA 3896/4885TSHR 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.